WELL Health、TerrAscend 和 Knight Therapeutics 公布了 2025 年第三季度强劲的业绩，收入和利润均有所增长，但 Knight Therapeutics 除外，该公司录得净亏损。 WELL Health, TerrAscend, and Knight Therapeutics reported strong Q3 2025 results with revenue and profit growth, except Knight Therapeutics, which posted a net loss.

WELL Health 报告称，2025 年第三季度收入达到创纪录的 3.646 亿美元，同比增长 56%，调整后 EBITDA 增长 296% 至 5990 万美元。 WELL Health reported record Q3 2025 revenue of $364.6 million, a 56% increase year-over-year, with Adjusted EBITDA rising 296% to $59.9 million. TerrAscend公布的净收入为6 510万美元,毛额差值从110个基点增至52.1%,业务现金净额为710万美元。 TerrAscend posted $65.1 million in net revenue, a 110-basis-point improvement in gross margin to 52.1%, and generated $7.1 million in net cash from operations. 骑士治疗学的收入增长32%,达到1.215亿美元,但报告净损失380万美元,而上一年的利润微乎其微。 Knight Therapeutics saw revenue grow 32% to $121.5 million but reported a net loss of $3.8 million, compared to a small profit in the prior year. 所有结果都是2025年9月30日结束的季度的结果。 All results are for the quarter ended September 30, 2025.